CompletedPhase 2

Beta Agonist Nebulization in Non Invasively Ventilated COPD Patients: Safety, and Therapeutic Efficacy Range.

France43 participantsStarted 2012-02

Plain-language summary

randomized double-blind controlled study in parallel groups Salbutamol is a β2 mimetic short-acting to be administered by nebulization in this study. During this administration, non invasive ventilation for the patient will be continued.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient over 18 years old * Patient with BPCO, defined: * by an irreversible obstructive syndrome * and\\or by different arguments (histories, symptoms, physical examination, thoracic radiography, gas of the blood) * Decompensation of this BPCO in the form of acute respiratory failure * No argument for a dominant acute left cardiac insufficiency * Consent signed by the patient * Patient with national health assurance Exclusion Criteria: * Contraindications in the not invasive ventilation * Patient not volunteer for the realization of the spirometry * Precautions for use of ß2 mimetic (engrave hyperthyroidism) * Under guardianship patient or protection of justice * Pregnant patient

What they're measuring

Collection at the bedside spirometric values

Timeframe: gross change in forced expiratory volume in one second from the beginning of salbutamol or placebo and 15 min after the start

Trial details

NCT IDNCT01958814

SponsorUniversity Hospital, Tours

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-07

View on ClinicalTrials.gov More Chronic Respiratory Failure trials